Lord Abbett & CO. LLC Has $215.53 Million Position in Abbott Laboratories $ABT

Lord Abbett & CO. LLC cut its position in Abbott Laboratories (NYSE:ABT) by 17.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,720,249 shares of the healthcare product maker’s stock after selling 364,297 shares during the quarter. Lord Abbett & CO. LLC owned 0.10% of Abbott Laboratories worth $215,530,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABT. Freemont Management S.A. boosted its position in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after buying an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $116,580,000. Thrivent Financial for Lutherans boosted its position in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after buying an additional 48,286 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in Abbott Laboratories in the third quarter valued at approximately $185,640,000. Finally, Net Worth Advisory Group acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $1,366,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Down 2.0%

Shares of NYSE ABT opened at $87.89 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06. The firm has a 50 day moving average price of $91.46 and a two-hundred day moving average price of $107.98. The stock has a market cap of $153.08 billion, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 1.50 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the company posted $1.09 EPS. The company’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research analyst reports. Jefferies Financial Group cut their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Argus cut their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. The Goldman Sachs Group cut their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research report on Wednesday, April 22nd. Finally, UBS Group decreased their price target on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $118.38.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.